Insider Buying: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Buys 15,666 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Bros. Advisors Lp Baker bought 15,666 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were acquired at an average price of $367.71 per share, with a total value of $5,760,544.86. Following the completion of the transaction, the director directly owned 1,964,542 shares of the company’s stock, valued at $722,381,738.82. This trade represents a 0.80% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Friday, November 6th, Bros. Advisors Lp Baker bought 76,140 shares of Madrigal Pharmaceuticals stock. The shares were acquired at an average cost of $384.32 per share, with a total value of $29,262,124.80.

Madrigal Pharmaceuticals Stock Performance

MDGL traded down $0.47 during trading on Friday, hitting $399.63. The company’s stock had a trading volume of 1,087,445 shares, compared to its average volume of 352,856. The business’s 50 day simple moving average is $489.63 and its 200-day simple moving average is $497.94. The firm has a market cap of $9.28 billion, a PE ratio of -66.83 and a beta of -0.98. Madrigal Pharmaceuticals, Inc. has a one year low of $353.54 and a one year high of $615.00. The company has a quick ratio of 2.94, a current ratio of 3.05 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. The firm had revenue of $431.27 million during the quarter, compared to the consensus estimate of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same quarter in the previous year, the firm posted ($5.08) EPS. As a group, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -6.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd bought a new stake in shares of Madrigal Pharmaceuticals in the second quarter worth about $29,000. Global Retirement Partners LLC bought a new stake in Madrigal Pharmaceuticals in the second quarter worth $34,000. Jacobi Capital Management LLC purchased a new stake in Madrigal Pharmaceuticals during the third quarter valued at $54,000. Provenance Wealth Advisors LLC purchased a new stake in Madrigal Pharmaceuticals during the third quarter valued at $69,000. Finally, Root Financial Partners LLC purchased a new stake in Madrigal Pharmaceuticals during the third quarter valued at $82,000. Institutional investors own 98.50% of the company’s stock.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Wolfe Research upgraded Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price objective for the company in a research note on Tuesday, August 4th. HC Wainwright assumed coverage on shares of Madrigal Pharmaceuticals in a report on Wednesday. They issued a “strong-buy” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 15th. Citigroup raised their price target on Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Barclays lowered their price objective on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $706.87.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.